Pharmaceutical formulations of hdac inhibitors

Details Pharmaceutical formulations of hdac inhibitors Pharmaceutical formulations of hdac inhibitors

A - Human Necessities

61

K

A61K 31/18 (2006.01) A61K 47/18 (2006.01) A61K 47/26 (2006.01) A61K 47/40 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2606598

This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

L'invention concerne des compositions pharmaceutiques comprenant certains composés à base d'acide carbamique (p. ex., ceux qui inhibent l'activité de HDAC (histone désacétylase)) (p.ex., PXD-101, N hydroxy-3-(3-phénylsulfamoyl-phényl)-acrylamide)) et un ou plusieurs ingrédients sélectionnés parmi cyclodextrine, arginine et méglumine. La présente invention concerne aussi l'utilisation de ces composés, par exemple, dans l'inhibition de HDAC et dans le traitement d'états à médiation par HDAC, du cancer, des états proliférants, du psoriasis, etc.

Affiliated with

Also associated with

Rating

Pharmaceutical formulations of hdac inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulations of hdac inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations of hdac inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1931472